- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Y mAbs Therapeutics (YMAB)
Assess today's live Y mAbs Therapeutics (YMAB) share price, performance and insights using our live NASDAQ: YMAB stock exchange data.
Analyse the historical data and Y mAbs Therapeutics share price performance charts on this page. Our technical summary section provides analysis on Y mAbs Therapeutics share price buy/sell indicators using real-time data (or discuss the Y mAbs Therapeutics (YMAB) stock price today with other investors in the Y mAbs Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ YMAB share price (ISIN: US9842411095) to enhance your trading decisions with our free investment tools and resources.
What Is the Y mAbs Therapeutics Share Price Today?
The Y mAbs Therapeutics share price today is 4.63.
What Is the Stock Symbol for Y mAbs Therapeutics
The stock symbol (or 'ticker') for Y mAbs Therapeutics is "YMAB."
What Stock Exchange Does Y mAbs Therapeutics Trade On?
Y mAbs Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Y mAbs Therapeutics a Good Stock to Buy?
Determining whether Y mAbs Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Y mAbs Therapeutics share price performance charts on this page. Our technical summary section provides analysis on Y mAbs Therapeutics share price buy/sell indicators using real-time data (or discuss the Y mAbs Therapeutics (YMAB) stock price today with other investors in the Y mAbs Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ YMAB share price (ISIN: US9842411095) to enhance your trading decisions with our free investment tools and resources.
What Is the Y mAbs Therapeutics Share Price Today?
The Y mAbs Therapeutics share price today is 4.63.
What Is the Stock Symbol for Y mAbs Therapeutics
The stock symbol (or 'ticker') for Y mAbs Therapeutics is "YMAB."
What Stock Exchange Does Y mAbs Therapeutics Trade On?
Y mAbs Therapeutics is listed and trades on the NASDAQ stock exchange.
Is Y mAbs Therapeutics a Good Stock to Buy?
Determining whether Y mAbs Therapeutics—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
4.63
-0.17(-3.54%)
Closed·
After Hours
4.72+0.09(+1.94%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.55
4.96
52 wk Range
3.55
16.11
YMAB Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
YMAB is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.554.96
52 wk Range
3.5516.11
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
YMAB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
14.70
Upside
+217.49%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
6 analysts have revised their earnings downwards for the upcoming period
Y mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Y mAbs Therapeutics SWOT Analysis
Antibody Innovato | Y-mAbs Therapeutics pioneers novel antibody therapies for cancer, with FDA-approved DANYELZA and promising SADA PRIT technology pipeline |
Market Challenges | Explore Y-mAbs' strategies to overcome slow DANYELZA growth and fierce competition in the neuroblastoma treatment market |
Financial Outlook | Analyst projections show revenue growth to $97M by 2025, with price targets ranging from $3 to $26 per share |
Future Prospects | Delve into Y-mAbs' SADA PRIT platform potential, international expansion plans, and extended cash runway through 2027 |
Y mAbs Therapeutics Earnings Call Summary for Q4/2024
- YmAbs Q4 2024 EPS -0.15, revenue $24.5M, both missing forecasts; stock drops 13.29% to $4.5 in premarket trading
- Danielza maintains 15-17% U.S. market share; international revenue shows growth in Western Asia, Latin America, and China
- 2025 revenue guidance $75-$90M; Q1 2025 expected $18-$21M; total operating expenses projected $116-$121M
- Management confident in cash runway through 2027; SADA platform trials show promising results
- Competitive pressures and decreasing cash reserves pose challenges; stock appears undervalued per InvestingPro analysis
Last Updated: 04/03/2025, 14:10
Read Full TranscriptCompare YMAB to Peers and Sector
Metrics to compare | YMAB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipYMABPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.4x | −4.9x | −0.5x | |
PEG Ratio | 0.28 | 0.00 | 0.00 | |
Price/Book | 2.3x | 0.6x | 2.6x | |
Price / LTM Sales | 2.4x | 4.9x | 3.0x | |
Upside (Analyst Target) | 227.0% | 321.2% | 51.5% | |
Fair Value Upside | Unlock | 33.1% | 9.4% | Unlock |
Analyst Ratings
8 Buy
0 Hold
2 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.70
(+217.49% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.12 / -0.1911
Revenue / Forecast
20.90M / 20.84M
People Also Watch
FAQ
What Is the Y mAbs Therapeutics (YMAB) Stock Price Today?
The Y mAbs Therapeutics stock price today is 4.63
What Stock Exchange Does Y mAbs Therapeutics Trade On?
Y mAbs Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Y mAbs Therapeutics?
The stock symbol for Y mAbs Therapeutics is "YMAB."
What Is the Y mAbs Therapeutics Market Cap?
As of today, Y mAbs Therapeutics market cap is 210.63M.
What Is Y mAbs Therapeutics's Earnings Per Share (TTM)?
The Y mAbs Therapeutics EPS (TTM) is -0.63.
When Is the Next Y mAbs Therapeutics Earnings Date?
Y mAbs Therapeutics will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is YMAB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Y mAbs Therapeutics Stock Split?
Y mAbs Therapeutics has split 0 times.
How Many Employees Does Y mAbs Therapeutics Have?
Y mAbs Therapeutics has 104 employees.
What is the current trading status of Y mAbs Therapeutics (YMAB)?
As of 19 Jun 2025, Y mAbs Therapeutics (YMAB) is trading at a price of 4.63, with a previous close of 4.80. The stock has fluctuated within a day range of 4.55 to 4.96, while its 52-week range spans from 3.55 to 16.11.
What Is Y mAbs Therapeutics (YMAB) Price Target According to Analysts?
The average 12-month price target for Y mAbs Therapeutics is USD14.7, with a high estimate of USD26 and a low estimate of USD3. 8 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Buy. The stock has an +217.49% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.